+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
India Anti-rheumatic Drug Market Forecasts from 2023 to 2028 - Product Thumbnail Image

India Anti-rheumatic Drug Market Forecasts from 2023 to 2028

  • Report
  • October 2023
  • 75 Pages
  • India
From
From
Canada Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Canada Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027

  • Report
  • September 2022
  • 77 Pages
  • Canada
From
Japan Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Japan Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027

  • Report
  • September 2022
  • 73 Pages
  • Japan
From
Crohns Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Crohns Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 100 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Knee osteoarthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Knee osteoarthritis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
US HUMIRA Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

US HUMIRA Market Size, Forecast, and Market Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • United States
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
OLUMIANT Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OLUMIANT Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
HUMIRA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

HUMIRA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Adalimumab Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Adalimumab Drugs Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 140 Pages
  • Global
From
HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031 - Product Thumbnail Image

HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more